scholarly journals Implementing virtual experiences and remote assessments during the COVID-19 pandemic: A college experience

2020 ◽  
pp. 54-55 ◽  
Author(s):  
M.N. Daftary ◽  
J. Jorden ◽  
M. Habib ◽  
I. Pather ◽  
T. Tofade
Keyword(s):  
Clinical Decision Making ◽  
Digital Health ◽  
Clinical Decision ◽  
Academic Planning ◽  
Face To Face ◽  
Howard University ◽  
Virtual Experiences ◽  
The Cost ◽  
Student Reflections ◽  
Remote Learning

With nine weeks remaining in the term, COVID-19 necessitated emergency remote learning and remote online exams. This required a series of software trainings for administrators, faculty and students at Howard University College of Pharmacy, USA. The experiential department also had to look beyond normal clerkship placements. The described telemedicine and virtual experiences were used to supplement face-to-face experiences. Assessments for both learning innovations were successful, based on faculty and student feedback. Student reflections describe how COVID-19 helped advance the use of telehealth and indicate their learning of clinical decision-making skills, effective communication, and the digital health industry. A formal evaluation of outcomes from the implemented pandemic innovations is being planned. The use of online proctoring with artificial intelligence during the emergency remote learning was successful. With software training, this type of service can be adopted to ensure the integrity of assessments. The cost of the service and the reporting time should be considered in academic planning.

scholarly journals Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma

2019 ◽  
Vol 104 (9) ◽  
pp. 3812-3820 ◽  
Author(s):  
Dipti Rao ◽  
Anouk van Berkel ◽  
Ianthe Piscaer ◽  
William F Young ◽  
Lucinda Gruber ◽  
...  
Keyword(s):  
Decision Making ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Diagnostic Value ◽  
Mibg Scintigraphy ◽  
Cross Sectional ◽  
First Choice ◽  
Cross Sectional Imaging ◽  
The Cost ◽  
The Impact

Abstract Context Cross-sectional imaging with CT or MRI is regarded as a first-choice modality for tumor localization in patients with pheochromocytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-MIBG) is widely used for functional imaging but the added diagnostic value is controversial. Objective To establish the virtual impact of adding 123I-MIBG scintigraphy to CT or MRI on diagnosis and treatment of PPGL. Design International multicenter retrospective study. Intervention None. Patients Two hundred thirty-six unilateral adrenal, 18 bilateral adrenal, 48 unifocal extra-adrenal, 12 multifocal, and 26 metastatic PPGL. Main Outcome Measures Patients underwent both anatomical imaging (CT and/or MRI) and 123I-MIBG scintigraphy. Local imaging reports were analyzed centrally by two independent observers who were blinded to the diagnosis. Imaging-based diagnoses determined by CT/MRI only, 123I-MIBG only, and CT/MRI combined with 123I-MIBG scintigraphy were compared with the correct diagnoses. Results The rates of correct imaging-based diagnoses determined by CT/MRI only versus CT/MRI plus 123I-MIBG scintigraphy were similar: 89.4 versus 88.8%, respectively (P = 0.50). Adding 123I-MIBG scintigraphy to CT/MRI resulted in a correct change in the imaging-based diagnosis and ensuing virtual treatment in four cases (1.2%: two metastatic instead of nonmetastatic, one multifocal instead of single, one unilateral instead of bilateral adrenal) at the cost of an incorrect change in seven cases (2.1%: four metastatic instead of nonmetastatic, two multifocal instead of unifocal and one bilateral instead of unilateral adrenal). Conclusions For the initial localization of PPGL, the addition of 123I-MIBG scintigraphy to CT/MRI rarely improves the diagnostic accuracy at the cost of incorrect interpretation in others, even when 123I-MIBG scintigraphy is restricted to patients who are at risk for metastatic disease. In this setting, the impact of 123I-MIBG scintigraphy on clinical decision-making appears very limited.

scholarly journals Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China

2021 ◽  
Vol 12 ◽  
Author(s):  
Ke-Xin Sun ◽  
Bin Cui ◽  
Shan-Shan Cao ◽  
Qi-Xiang Huang ◽  
Ru-Yi Xia ◽  
...  
Keyword(s):  
Decision Making ◽  
Sensitivity Analysis ◽  
Cost Effectiveness ◽  
Markov Model ◽  
Clinical Decision Making ◽  
Cost Effective ◽  
Clinical Decision ◽  
Base Case ◽  
Effectiveness Analysis ◽  
The Cost

Background: The drug therapy of venous thromboembolism (VTE) presents a significant economic burden to the health-care system in low- and middle-income countries. To understand which anticoagulation therapy is most cost-effective for clinical decision-making , the cost-effectiveness of apixaban (API) versus rivaroxaban (RIV), dabigatran (DAB), and low molecular weight heparin (LMWH), followed by vitamin K antagonist (VKA), in the treatment of VTE in China was assessed.Methods: To access the quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs), a long-term cost-effectiveness analysis was constructed using a Markov model with 5 health states. The Markov model was developed using patient data collected from the Xijing Hospital from January 1, 2016 to January 1, 2021. The time horizon was set at 30 years, and a 6-month cycle length was used in the model. Costs and ICERs were reported in 2020 U.S. dollars. One-way sensitivity analysis and probabilistic sensitivity analysis (PSA) were used to test the uncertainties. A Chinese health-care system perspective was used.Results: In the base case, the data of 231 VTE patients were calculated in the base case analysis retrospectively. The RIV group resulted in a mean VTE attributable to 95% effective treatment. API, DAB, and VKA have a negative ICER (−187017.543, −284,674.922, and −9,283.339, respectively) and were absolutely dominated. The Markov model results confirmed this observation. The ICER of the API and RIV was negative (−216176.977), which belongs to the absolute inferiority scheme, and the ICER value of the DAB and VKA versus RIV was positive (110,577.872 and 836,846.343). Since the ICER of DAB and VKA exceeds the threshold, RIV therapy was likely to be the best choice for the treatment of VTE within the acceptable threshold range. The results of the sensitivity analysis revealed that the model output varied mostly with the cost in the DAB on-treatment therapy. In a probabilistic sensitivity analysis of 1,000 patients for 30 years, RIV has 100% probability of being cost-effective compared with other regimens when the WTP is $10973 per QALY. When WTP exceeded $148,000, DAB was more cost-effective than RIV.Conclusions: Compared with LMWH + VKA and API, the results proved that RIV may be the most cost-effective treatment for VTE patients in China. Our findings could be helpful for physicians in clinical decision-making to select the appropriate treatment option for VTE.

Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non- Hodgkin lymphoma (NHL)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8089-8089 ◽  
Author(s):  
C. R. Flowers ◽  
J. C. Sambrook ◽  
A. Briggs ◽  
K. Osenenko ◽  
H. Wang ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Alternative Therapies ◽  
Cost Of Care ◽  
Low Grade ◽  
Life Years ◽  
Weibull Models ◽  
Third Line ◽  
The Cost

8089 Background: BTR has demonstrated efficacy in NHL patients and it has potential to prolong time to progression (TTP) in relapsed/refractory, low grade, follicular, or transformed NHL. This study assessed effectiveness and cost-effectiveness of BTR compared to alternative therapies in first, second, and third line NHL therapy. Methods: Time-to-event models were constructed with 2 events: progression and death. Patient data from 8 BTR clinical trials were combined to fit Weibull models for TTP and overall survival (OS) by including FLIPI covariates. Estimates for BTR were compared with estimates for alternatives from Weibull models fitted to published TTP and BTR OS data by lines of therapy and measured in life-years (LY). Estimated pre-progression costs included drug costs, lab tests, monitoring, and adverse events; post progression costs included NHL costs until death, all valued in 2006 $US and discounted at 3%. Indirect comparisons yielded incremental cost-effectiveness ratios (ICER=Δ cost/Δ LYs) in each line of therapy. Results: As observed in the table , cost of care estimates in BTR were often comparable with alternative therapies, but typically LY gain favored BTR. Mostly in first and third line, a BTR strategy had an ICER less than the cost-effectiveness threshold of $50,000 per LY gained. Conclusion: Overall, a BTR strategy has a favorable cost-effectiveness profile to alternative strategies including rituximab maintenance (RXM) in first, second, and third line NHL therapy. Results imply both a possible survival gain with early BTR use, and the cost-effectiveness of BTR. This modeling approach can aid in clinical decision making regarding the sequence and timing of therapy for patients with follicular NHL. No significant financial relationships to disclose. [Table: see text]

Understanding engagement and potential impact of an electronic drug repository: A mixed-methods study. (Preprint)

2021 ◽  
Author(s):  
Charlene Soobiah ◽  
Michelle Phung ◽  
Mina Tadrous ◽  
Trevor Jamieson ◽  
R. Sacha Bhatia ◽  
...  
Keyword(s):  
Online Survey ◽  
Clinical Decision Making ◽  
Point Of Care ◽  
Digital Health ◽  
Inappropriate Prescribing ◽  
Clinical Decision ◽  
Qualitative Description ◽  
Structured Interviews ◽  
Clinical Value ◽  
Secondary Information

BACKGROUND Centralized drug repositories can reduce adverse events and inappropriate prescribing by enabling access to dispensed medication data at the point-of-care, but how they achieve this goal is largely unknown. OBJECTIVE To understand 1) the perceived clinical value; 2) the barriers and enablers to adoption; and 3) for which clinician groups a provincial, centralized drug repository may provide the most benefit. METHODS A mixed-method approach, including an online survey and semi-structured interviews, was employed. Participants were clinicians (e.g., nurses, physicians, and pharmacists) in Ontario who were eligible to use the Digital Health Drug Repository (DHDR), irrespective of actual use. Survey data were ranked on a 7-point adjectival scale and analyzed using descriptive statistics and interviews were analyzed using qualitative description. RESULTS : Of 167 survey respondents, only 24% (n=40) were actively using the DHDR. Perceptions of the utility of the DHDR were neutral (mean scores ranged from 4.11-4.76). Of the 76% who were not using the DHDR, 98% rated access to medication information (e.g., dose, strength, frequency) as important. Reasons for not using the DHDR included the cumbersome access process and the perception that available data was incomplete or inaccurate. A total of 33 interviews were completed, of which 26 were active DHDR users. The DHDR was a satisfactory source of secondary information, but the absence of medication instructions and prescribed medications (that were not dispensed) limited its ability to provide a comprehensive profile in order to meaningfully support clinical decision-making. CONCLUSIONS Digital drug repositories must adjust to align with clinician needs to provide value. Ensuring (1) integration with point-of-care systems; (2) comprehensive clinical data; and (3) streamlined onboarding processes would optimize clinically meaningful use. The electronic provision of accessible drug information to providers across healthcare settings has the potential to improve efficiency and reduce medication errors. CLINICALTRIAL N/A

Data Mining and Analysis of Lung Cancer

2010 ◽  
pp. 118-144
Author(s):  
Guoxin Tang
Keyword(s):  
Lung Cancer ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
The United States ◽  
Claim Data ◽  
National Database ◽  
Appropriate Treatment ◽  
The World ◽  
The Cost ◽  
The Relationship

Lung cancer is the leading cause of cancer death in the United States and the world, with more than 1.3 million deaths worldwide per year. However, because of a lack of effective tools to diagnose lung cancer, more than half of all cases are diagnosed at an advanced stage, when surgical resection is unlikely to be feasible. The purpose of this study is to examine the relationship between patient outcomes and conditions of the patients undergoing different treatments for lung cancer and to develop models to estimate the population burden, the cost of cancer, and to help physicians and patients determine appropriate treatment in clinical decision-making. We use a national database, and also claim data to investigate treatments for lung cancer.

OP199 From Pilot Studies To System-Wide Innovation: Challenges And Opportunities For Clinical Decision Support Systems (CDSS) Implementation In Australia

2021 ◽  
Vol 37 (S1) ◽  
pp. 5-6
Author(s):  
Mah Laka ◽  
Adriana Milazzo ◽  
Drew Carter ◽  
Tracy Merlin
Keyword(s):  
Decision Support ◽  
Decision Support Systems ◽  
Clinical Decision Support ◽  
Clinical Decision Making ◽  
Support Systems ◽  
Digital Health ◽  
National Level ◽  
Clinical Decision Support Systems ◽  
Clinical Decision ◽  
Policy Framework

IntroductionThe clinical data is increasing at a considerably higher rate than the capacity of the healthcare system and clinicians to manage this data. Digital tools such as clinical decision support systems (CDSS) provide opportunities for evidence-based patient care by intelligently filtering and presenting the information required for clinical decision making at the point of care. Despite the success of pilot projects, CDSS have had limited implementation in broader health systems. We aimed to identify challenges faced by policymakers for CDSS implementation and to provide policy recommendations.MethodsWe conducted eleven semi-structured interviews with Australian policymakers from state and national committees involved in digital health activities. The data were analyzed using reflexive thematic analysis to identify policy priorities.ResultsOur findings indicate that fragmentation of care processes and structures in the digital health ecosystem is one of the main impediments to delivering coordinated care using CDSS. Five themes for policy action were identified: (i) establishing a shared conceptual framework for user-centered design of CDSS that is aligned with stakeholders’ priorities, (ii) maintaining the right balance between the customization and standardization of systems, (iii) developing mutually agreed semantic interoperability standards at the local, state and national level, allowing generation and exchange of information across the health system without changing its context and meaning, (iv) reorienting organizational structures to build capacity to foster change, and (v) developing collaborative care models to avoid conflicting interests between stakeholders.ConclusionsFindings highlight the importance of developing system-wide guidance to establish a clear vision for CDSS implementation and alignment of organizational processes across all levels of health care. There is a need to build a shared policy framework for modelling the innovative activities such as CDSS implementation across the digital health landscape which minimizes the operational and strategic fragmentation of different organizations.

scholarly journals Evaluation of the Clinical Curative Effect of an O2-O3 mixture to Treat Lumbar Disc Herniation with Different Treatment Sessions

2009 ◽  
Vol 15 (2) ◽  
pp. 159-163 ◽  
Author(s):  
L. Xu ◽  
Z-L. Li ◽  
X-F. He ◽  
D-C. Xiang ◽  
J. Ma ◽  
...  
Keyword(s):  
Lumbar Disc Herniation ◽  
Disc Herniation ◽  
Clinical Decision Making ◽  
Lumbar Disc ◽  
Clinical Decision ◽  
Effective Rate ◽  
Ozone Therapy ◽  
Curative Effect ◽  
Significant Difference ◽  
The Cost

To compare the effective rates among one week, two week and four week treatment sessions of ozone therapy for lumbar disc herniation to provide a foundation for clinical decision-making. One hundred and eighty-seven lumbar disc herniation patients were divided into three groups, 103 cases for one week, 61 cases for two week and 23 cases for four week treatment sessions. The clinical curative effective rates in the three groups were 82.52%, 85.24% and 95.65% respectively. The effective rate among the three groups showed no significant difference at statistical analysis. Considering the cost-effectiveness of ozone therapy, increasing the treatment course does not enhance the curative effect.

scholarly journals Diagnostics 4.0: the medical laboratory in digital health

2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Michael Neumaier
Keyword(s):  
Health Care ◽  
Clinical Decision Making ◽  
Digital Health ◽  
Preventive Health Care ◽  
Clinical Decision ◽  
Laboratory Medicine ◽  
Cloud Services ◽  
Added Value ◽  
Medical Laboratory ◽  
The Way

AbstractDuring recent years, the digital revolution has changed the face of societies including industrial production, economies and peoples’ social lives. From these changes we may extrapolate the developments that digitization of health care will bring to medicine in general and laboratory medicine in particular. Disruptive technologies will fundamentally change the way laboratory tests are going to be ordered, carried out and interpreted in the future, and test results from various sources need to be curated to be of added value for the patient’s condition. Wearables and implantables will quantify the concentrations for an unknown number of laboratory parameters, and the data will be stored in cloud services at the fingertips of the patient as the sovereign of his/her health care data. A 24/7 online availability of health services will strengthen predictive medicine and may enable a vastly improved preventive health care that is supported by deep-learning algorithms for clinical decision-making not only on behalf of the physician, but also the empowered patient (e.g. health bots). This will likely shift the current role of Laboratory Medicine as a central provider of diagnostic information from a “hidden champion” towards a higher visibility redefining the patient-physician-laboratory relationship. For example, accessing digital health data will allow Laboratory Medicine to more efficiently contribute to the medical dialog than is often the case today. From this perspective, this will require major readjustments in the way we execute our profession, and it will also need new concepts of education and continuous professional development.

scholarly journals An exploration of the role of advanced clinical practitioners in the East of England

2020 ◽  
Vol 29 (15) ◽  
pp. 864-869
Author(s):  
Claire Hooks ◽  
Susan Walker
Keyword(s):  
Clinical Decision Making ◽  
Clinical Decision ◽  
Self Awareness ◽  
The Uk ◽  
The Cost ◽  
High Degree ◽  
Individual Accountability

Medical staff shortages in the UK have provided impetus for the introduction of advanced clinical practitioners (ACPs). This case study explored the views of 22 ACPs, managers and doctors in primary and acute settings in a region of England, to understand how the role is used, and barriers and facilitators to its success. ACP roles improved the quality of service provision, provided clinical career development and enhanced job satisfaction for staff and required autonomous clinical decision-making, with a high degree of self-awareness and individual accountability. Barriers included disparate pay-scales and funding, difficulty accessing continuing education and research, and lack of agreed role definition and title, due to a lack of standardised regulation and governance, and organisational barriers, including limited access to referral systems. Facilitators were supportive colleagues and opportunities for peer networking. Regulation of ACP roles is urgently needed, along with evaluation of the cost-effectiveness and patient experience of such roles.

Sign in / Sign up

Export Citation Format

Share Document